The chapters in this monograph detail the past, present and potential future of markers used for the detection of myocardial injury and for risk assessment as part of a cardiovascular disease work-up strategy. The strengths of this extensive overview, written by many of the current leaders in the field, lie in the evidence presented in addressing analytical/technical, clinical, and outcome-assessments of each biomarker currently used in clinical practice, and for those being investigated as potential cutting-edge tools.
The chapters in this monograph detail the past, present and potential future of markers used for the detection of myocardial injury and for risk assessment as part of a cardiovascular disease work-up strategy. The strengths of this extensive overview, written by many of the current leaders in the field, lie in the evidence presented in addressing analytical/technical, clinical, and outcome-assessments of each biomarker currently used in clinical practice, and for those being investigated as potential cutting-edge tools.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Jesse E. Adams, MD, FACC, is with the University of Louisville, Division of Cardiology. He has published scientific papers in multiple journals including the New England Journal of Medicine and the Journal of the American College of Cardiology. Fred S. Apple, PhD, is with the Department of Laboratory Medicine and Pathology at Hennepin County Medical Center. He is a professor at the University of Minnesota Department of Laboratory Medicine and Pathology. Dr. Apple also serves as an Associate Editor for the journal Clinical Chemistry.
Inhaltsangabe
Chapter 1. Analytical Issues Affecting the Clinical Performance of Cardiac Troponin Assays - Alan H.B. Wu PhD. Chapter 2. Prepare To Meet Your Markers: Making the Most out of Troponin I Degradation - Jason L. McDonough BSc(H) Ralf Labugger MSc and Jennifer E. Van Eyk PhD. Chapter 3. Functional Sensitivity of Cardiac Troponin Assays and its Implications for Risk-Stratification for Patients with Acute Coronary Syndromes - Kiang-Teck J. Yeo PhD Kelly S. Quinn-Hall MT Stephanie W. Bateman BA George A. Fischer PhD Stacey Wieczorek PhD and Alan H.B. Wu PhD. . Chapter 4. Report on a Survey of Analytical and Clinical Characteristics of Commercial Cardiac Troponin Assays - Fred S. Apple PhD Jesse E. Adams III MD Alan H.B. Wu PhD and Allan S. Jaffe MD. Chapter 5. The Current Assessment of Qualitative and Quantitative Point-of-Care Testing of Cardiac Markers - Roland Valdes Jr PhD and Saeed A. Jortani PhD. Chapter 6. Acute Coronary Syndromes: Pathophysiology Clinical Presentation and Initial Diagnostic Strategies - Jesse E. Adams III MD and Vickie A. Miracle RN EdD. Chapter 7. WHO Criteria: Where Do We Go from Here? - Allan S. Jaffe MD. Chapter 8. An Integrated Diagnostic Approach to the Patient with Chest Pain - Robert L. Jesse MD PhD and Michael C. Kontos MD. Chapter 9. The Use of Cardiac Markers for Therapeutic Decisions in Acute Coronary Syndromes - Michael P. Hudson MD Britta U. Goldmann MD E. Magnus Ohman MD. Chapter 10. The Evaluation of Acute Coronary Syndrome in the Emergency Department: The Impact of Cardiac Biomarkers and ST-Segment Trend Monitoring - David A. Grundy MD and W. Brian Gibler MD. Chapter 11. Cardiac Troponin T in Coronary Artery Disease: Where Do We Stand? Evangelos Giannitsis MD Britta Weidtmann MD Margit Müller-Bardorff MD Norbert Frey MD and Hugo A. Katus MD. Chapter 12. Creatine Kinase: A Marker for the Early Diagnosis of Acute Myocardial Infarction - Robert Fromm MD MPH and Robert Roberts MD. Chapter 13. Fatty Acid Binding Protein as a Plasma Marker for the Early Assessment of Individuals with Acute Coronary Syndromes - Jan F.C. Glatz PhD and Wim T. Hermens PhD. Chapter 14. Oxidized Low-Density Lipoprotein and Malondialdehyde-Modified Low-Density Lipoprotein: Markers of Coronary Artery Disease - Paul Holvoet PhD Frans Van de Werf MD PhD Johan Vanhaecke MD PhD and Désiré Collen MD PhD. Chapter 15. High-Sensitivity C-Reactive Protein: A Novel Inflammatory Marker for Predicting the Risk of Coronary Artery Disease - Paul M. Ridker MD MPH. Chapter 16. Nuclear Factor Kappa B: A Marker of Coronary Artery Disease Activity? - George K. Daniel MD Richa Gupta MD Jessica Gillespie BS Rose Felten BS Linda Cise MS Kathy Sturdevant BS and Michael E. Ritchie MD. Chapter 17. The Use of Troponins to Detect Cardiac Injury after Cardiac and Noncardiac Surgery - Jesse E. Adams III MD. Chapter 18. The Role of Cardiac Troponin Testing in Renal Disease - Fred S. Apple PhD. . Chapter 19. The Use of Cardiac Biomarkers for the Detection of Drug-Induced Myocardial Damage - Eugene H. Herman PhD and V.J. Ferrans MD PhD. Chapter 20. The Utility of Brain Natriuretic Peptides in Patients with Heart Failure and Coronary Artery Disease - Johannes Mair MD
Chapter 1. Analytical Issues Affecting the Clinical Performance of Cardiac Troponin Assays - Alan H.B. Wu PhD. Chapter 2. Prepare To Meet Your Markers: Making the Most out of Troponin I Degradation - Jason L. McDonough BSc(H) Ralf Labugger MSc and Jennifer E. Van Eyk PhD. Chapter 3. Functional Sensitivity of Cardiac Troponin Assays and its Implications for Risk-Stratification for Patients with Acute Coronary Syndromes - Kiang-Teck J. Yeo PhD Kelly S. Quinn-Hall MT Stephanie W. Bateman BA George A. Fischer PhD Stacey Wieczorek PhD and Alan H.B. Wu PhD. . Chapter 4. Report on a Survey of Analytical and Clinical Characteristics of Commercial Cardiac Troponin Assays - Fred S. Apple PhD Jesse E. Adams III MD Alan H.B. Wu PhD and Allan S. Jaffe MD. Chapter 5. The Current Assessment of Qualitative and Quantitative Point-of-Care Testing of Cardiac Markers - Roland Valdes Jr PhD and Saeed A. Jortani PhD. Chapter 6. Acute Coronary Syndromes: Pathophysiology Clinical Presentation and Initial Diagnostic Strategies - Jesse E. Adams III MD and Vickie A. Miracle RN EdD. Chapter 7. WHO Criteria: Where Do We Go from Here? - Allan S. Jaffe MD. Chapter 8. An Integrated Diagnostic Approach to the Patient with Chest Pain - Robert L. Jesse MD PhD and Michael C. Kontos MD. Chapter 9. The Use of Cardiac Markers for Therapeutic Decisions in Acute Coronary Syndromes - Michael P. Hudson MD Britta U. Goldmann MD E. Magnus Ohman MD. Chapter 10. The Evaluation of Acute Coronary Syndrome in the Emergency Department: The Impact of Cardiac Biomarkers and ST-Segment Trend Monitoring - David A. Grundy MD and W. Brian Gibler MD. Chapter 11. Cardiac Troponin T in Coronary Artery Disease: Where Do We Stand? Evangelos Giannitsis MD Britta Weidtmann MD Margit Müller-Bardorff MD Norbert Frey MD and Hugo A. Katus MD. Chapter 12. Creatine Kinase: A Marker for the Early Diagnosis of Acute Myocardial Infarction - Robert Fromm MD MPH and Robert Roberts MD. Chapter 13. Fatty Acid Binding Protein as a Plasma Marker for the Early Assessment of Individuals with Acute Coronary Syndromes - Jan F.C. Glatz PhD and Wim T. Hermens PhD. Chapter 14. Oxidized Low-Density Lipoprotein and Malondialdehyde-Modified Low-Density Lipoprotein: Markers of Coronary Artery Disease - Paul Holvoet PhD Frans Van de Werf MD PhD Johan Vanhaecke MD PhD and Désiré Collen MD PhD. Chapter 15. High-Sensitivity C-Reactive Protein: A Novel Inflammatory Marker for Predicting the Risk of Coronary Artery Disease - Paul M. Ridker MD MPH. Chapter 16. Nuclear Factor Kappa B: A Marker of Coronary Artery Disease Activity? - George K. Daniel MD Richa Gupta MD Jessica Gillespie BS Rose Felten BS Linda Cise MS Kathy Sturdevant BS and Michael E. Ritchie MD. Chapter 17. The Use of Troponins to Detect Cardiac Injury after Cardiac and Noncardiac Surgery - Jesse E. Adams III MD. Chapter 18. The Role of Cardiac Troponin Testing in Renal Disease - Fred S. Apple PhD. . Chapter 19. The Use of Cardiac Biomarkers for the Detection of Drug-Induced Myocardial Damage - Eugene H. Herman PhD and V.J. Ferrans MD PhD. Chapter 20. The Utility of Brain Natriuretic Peptides in Patients with Heart Failure and Coronary Artery Disease - Johannes Mair MD
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
